Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Haijun Cao
Observed name:
H. Cao
Institutions:
Zhejiang Chinese Medical University,
Zhejiang Provincial Hospital of TCM
Observed institutions:
Zhejiang Chinese Medical University,
Sun Yat-sen University,
Zhejiang Provincial Hospital of TCM,
Sun Yat-sen Memorial Hospital,
Anyang Tumor Hospital
ORCID:
0009-0000-2337-1478
Observed ORCID:
0009-0000-2337-1478
OpenAlex ID:
A5030518488
Efficacy of sorafenib plus transcatheter arterial chemoembolization in treating hepatocellular carcinoma with portal vein tumor thrombosis: A meta-analysis
2024
·
Li Xu
, Shanshan Chen
, et al.
·
Acta Pharmaceutica
·
5
PDF
863P Safety and efficacy of four courses of pembrolizumab combined with carboplatin and albumin-binding paclitaxel versus two courses of neoadjuvant therapy in patients with resectable head and neck squamous cell carcinoma: An optimal efficacy study (prospective, two-arm, phase II)
2024
·
J. Li
, H. Cao
, et al.
·
Annals of Oncology
·
3
Platelet count combined with Child-Turcotte-Pugh score for predicting rebleeding in cirrhotic patients with esophagogastric variceal bleeding
2026
·
Chao Yang
, Haijun Cao
, et al.
·
European journal of medical research
1252P Update results of anlotinib combined with nab-paclitaxel and cisplatin as neoadjuvant treatment for esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase Ⅱ clinical trial
2022
·
Y-F. Zhang
, X-B. Li
, et al.
·
Annals of Oncology
PDF
Show more works
View as search
Works count:
4
Citation count:
8
H-index:
2
I10-index:
Year
Topic
Type